Business
Latest Data From Phase 1 Trial of ProscaVax for Prostate Cancer Reinforces Safety and Benefit of Novel Cancer Vaccine
Latest Data From Phase 1 Trial of ProscaVax for Prostate Cancer Reinforces Safety and Benefit of Novel Cancer Vaccine.
About this update from Theralink Technologies Inc.
[{"type":"text","content":"\nLatest Data From Phase 1 Trial of ProscaVax for Prostate Cancer Reinforces Safety and Benefit of Novel Cancer Vaccine\n\nLatest Data From Phase 1 Trial of ProscaVax for Prostate Cancer Reinforces Safety and Benefit of Novel Cancer Vaccine\n\nBATON ROUGE, LA--(Marketwired - August 08, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) (\"OncBioMune\" or the \"Company\"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to provide the latest information from the Phase 1 clinical trial evaluating the Company's novel cancer vaccine, ProscaVax, in PSA (Prostate Specific Antigen) recurrent prostate cancer in both hormone-naïve and hormone-independent patients. The trial is being hosted at the University of California San Diego Moores Cancer Center and Veterans Hospital in La Jolla, California under an IND from the U.S. Food and Drug Administration with funding from the U.S. Navy Cancer Vaccine Program.To date, 16 patients have been enrolled in the Phase 1a trial. A strong safety profile has been established for ProscaVax. No serious adverse events have been reported in the trial, further validating prior research in hundreds of patients showing minimal toxicity of the Company's vaccine technology.Additional preliminary data from the trial shows ProscaVax to provide a meaningful clinical benefit to prostate cancer patients. These data include:15 of 20 patients in the Phase 1a portion of the trial have received at least one vaccine injection and 14 patients have received all 6 vaccinesNone of the 15 patients who have had at least one vaccine have had a dose limiting adverse event (DLAE)None of the 14 patients who have received all 6 vaccines in the Phase 1a have had a DLAE9 of the 12 patients (75%) who have received 6 vaccines have had increased immune responses to PSA as determined with a LBA (lymphocyte blastogenesis assay)9 of 11 patients (82%) at 31 weeks post first vaccine have had an increased immune response to PSA as determined with a LBAThree of the 14 patients who have received all 6 vaccines have experienced disease progression (one radiological, two PSA)The trial was originally designed as a Phase 1a/1b study with approximately 20 patients expected to be enrolled in the Phase 1a portion. As previously disclosed, based up...